$90MEquity raised, all time2 equity rounds sourced so far
—Latest valuationnot disclosed
Rounds over time log-scaled amounts
Funding history 2 rounds · 2 sources · newest first
Earlier rounds not yet sourced. AnaCardio raised before 9 Jan 2025; only the rounds below are sourced so far, so its all-time equity total understates its history.
Release gives EUR 62.5M only. USD converted at the ECB reference rate of 1.1355 USD per EUR on 2026-09-30 (announcement date), so approximate. Co-led by Novo Holdings and the Ljungstrom family office. Valuation not stated (pre- or post-money not stated). Company says it has raised around EUR 100M to date.
Novo Holdings, Pureos Bioventures, Sound Bioventures
Also
Flerie, Industrifonden, Fredrik Ljungström, Ann-Helene Ljungström
Note
Company release gives USD 19M (SEK 205M); the release itself states the amount in USD and SEK, so the USD figure is as stated. Novo Holdings, Pureos and Sound Bioventures co-led. Valuation not stated. Company newsroom lists it as an extension of the Series A (the SEK 50M second tranche completing an earlier Series A is not dated).
Figures in USD at the time of each round. See the methodology for how rounds are sourced and verified. AnaCardio and its logo are trademarks of their owners, used here for identification only.